 | | Vol. 11.45 – 17 November, 2020 |
| |
|
|
| Using a genome-wide CRISPR-Cas9 screen for effectors of CC-90009 response, researchers uncovered the ILF2 and ILF3 heterodimeric complex as a novel regulator of cereblon expression. Knockout of ILF2/ILF3 decreased the production of full-length cereblon protein via modulating CRBN mRNA alternative splicing, leading to diminished response to CC-90009.
[Blood] |
|
 |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors analyzed a unique collection of internal Xeroderma Pigmentosum group C (XP-C) tumor genomes including six leukemias and two sarcomas. They observed a specific mutational pattern and an average of 25-fold increase of mutation rates in XP-C versus sporadic leukemia which they presumed led to its elevated incidence and early appearance.
[Nature Communications] |
|
|
|
| Researchers report synergistic anti-leukemic activity of the BCL-2 inhibitor venetoclax and the asparaginase formulation Pegylated Crisantaspase in complex karyotype acute myeloid leukemia in vitro and in vivo.
[Leukemia] |
|
|
|
| Bone marrow studies showed binucleated erythroblasts and erythroblasts with cytoplasmic bridges indicating abnormal cytokinesis and abscission. Circulating red blood cells were found to retain transferrin receptor in their membrane, demonstrating that VPS4A is critical for normal reticulocyte maturation.
[American Journal of Human Genetics] |
|
|
|
| Researchers found that leukemic stem cells were highly differentiated, and leukemia progression was severely impaired in the absence of adenosyl methionine decarboxylase (AMD1) in vivo.
[Oncogene] |
|
|
|
| Scientists demonstrated that Pax5 heterozygosis, in the presence of infections, resulted in the enhanced production of the inflammatory cytokine interleukin-6, which appeared to act in an autocrine fashion to promote leukemia growth.
[Scientific Reports] |
|
|
|
| The authors used single-cell RNA sequencing to characterize the kinetics of the murine bone marrow microenvironment during B cell acute lymphoblastic leukemia progression. Normal pro- and pre-B cells were found to be the most affected at the earliest stages of disease and this was associated with changes in expression of genes regulated by the AP1-transcription factor complex and regulatory factors NELFE, MYC and BCL11A.
[Scientific Reports] |
|
|
|
| Scientists found that SN3-L6 induced transdifferentiation of both acute myeloid leukemia and chronic myelogenous leukemia cells but unexpectedly, a new transdifferentiation pathway from acute promyelocytic leukemia cells to morphologically and immunologically normal megakaryocytes and platelets were discovered.
[Cell Death Discovery] |
| |
|
|
| The authors evaluated the effect of a new pre-emptive tyrosine kinase inhibitors (TKIs) strategy on relapse in Philadelphia-chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients with complete remission undergoing allogeneic hematopoietic cell transplantation. Pre-emptive TKIs initiation was based on BCR/ABL molecular monitoring
[Leukemia] |
|
|
|
| Management of rare hematological disorders pose unique diagnostic and therapeutic challenges due to unusual occurrence and limited treatment options. Investigators retrospectively identified 45 patients receiving matched related donor transplant for rare hematological disorders from 2006 to 2019.
[Bone Marrow Transplantation] |
|
|
|
| Scientists report the outcome of 68 patients with advanced peripheral T-cell lymphoma receiving transplantation from haploidentical or from conventional donors. The four-year overall survival, progression free survival, two-year cumulative incidence of relapse and two-year GVHD and relapse free survival was 75%, 70%, 21%, and 51%, respectively.
[Bone Marrow Transplantation] |
|
 |
|
|
|
| Investigators review the current knowledge on the multiple functions that neutrophils exhibit through the different stages of allogeneic hematopoietic stem cell transplantation, from the hematopoietic stem cell (HSC) mobilization in the donor to the immunological reconstitution that occurs in the recipient following HSC infusion.
[Cellular & Molecular Immunology] |
|
|
|
| The author focusses on recent findings concerning Tet methylcytosine dioxygenase 2 (Tet2) involvement in lymphoid and myeloid cell development and its functional roles, which may be associated with tumorigenesis.
[Communications Biology] |
|
|
|
|
| PharmaTher, Inc. announced has filed a provisional patent application with the US Patent and Trademark Office outlining the potential novel use of psilocybin to treat cancer, which was discovered by panaceAI™, their proprietary psychedelic drug repurposing artificial intelligence platform.
[PharmaTher, Inc. (GlobeNewswire, Inc.)] |
|
|
|
|
| May 16 – May 21, 2021
Lucca, Italy |
|
|
|
|
|
| | Rubius Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
| | New York Blood Center – New York, New York, United States |
|
|
|
| | The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
